BRAF and cutaneous melanoma: Like in skin melanomas, NRAS and BRAF mutations are predominantly mutually exclusive in CMs [27,30,32,33,34,40], suggesting that the activating mutations in either of these two key molecules constitute the major oncogenic drivers through the MAPK (RAS/RAF/MEK/ERK) pathway.